Gene · 54567
Papers4,267
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 4,267
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Interleukin-6 and pulmonary hypertension: from physiopathology to therapy. | Front Immunol | 2023 | 37449201 | PubTator, text mining | PubMed |
| "DEPHENCE" system-a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer-a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies. | Front Oncol | 2023 | 37448521 | PubTator, text mining | PubMed |
| Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches. | Int J Mol Sci | 2023 | 37445860 | PubTator, text mining | PubMed |
| Clinical Potential of Mesenchymal Stem Cell-Derived Exosomes in Bone Regeneration. | J Clin Med | 2023 | 37445420 | PubTator, text mining | PubMed |
| Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment. | Cancers (Basel) | 2023 | 37444584 | PubTator, text mining | PubMed |
| Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications. | Cancers (Basel) | 2023 | 37444544 | PubTator, text mining | PubMed |
| Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency. | Theranostics | 2023 | 37441599 | PubTator, text mining | PubMed |
| Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies. | MedComm (2020) | 2023 | 37441462 | PubTator, text mining | PubMed |
| VEGF Mediates Tumor Growth and Metastasis by Affecting the Expression of E-Cadherin and N-Cadherin Promoting Epithelial to Mesenchymal Transition in Gastric Cancer. | Clin Med Insights Oncol | 2023 | 37435016 | PubTator, text mining | PubMed |
| Liver in infections: a single-cell and spatial transcriptomics perspective. | J Biomed Sci | 2023 | 37430371 | PubTator, text mining | PubMed |
| KRAS mutation-driven angiopoietin 2 bestows anti-VEGF resistance in epithelial carcinomas. | Proc Natl Acad Sci U S A | 2023 | 37428914 | PubTator, text mining | PubMed |
| An investigation into the role of Notch signaling, altered angiogenesis, and inflammatory-induced preterm delivery and related complications in Northeast Indian patients. | Placenta | 2023 | 37421871 | PubTator, text mining | PubMed |
| The signaling pathways of traditional Chinese medicine in treating diabetic retinopathy. | Front Pharmacol | 2023 | 37405050 | PubTator, text mining | PubMed |
| Microglia in Alzheimer's disease: pathogenesis, mechanisms, and therapeutic potentials. | Front Aging Neurosci | 2023 | 37396657 | PubTator, text mining | PubMed |
| Recent developments on BMPs and their antagonists in inflammatory bowel diseases. | Cell Death Discov | 2023 | 37391444 | PubTator, text mining | PubMed |
| Mesenchymal stem cells: An efficient cell therapy for tendon repair (Review). | Int J Mol Med | 2023 | 37387410 | PubTator, text mining | PubMed |
| Notch signaling drives intestinal graft-versus-host disease in mice and nonhuman primates. | Sci Transl Med | 2023 | 37379368 | PubTator, text mining | PubMed |
| Gastrointestinal Manifestations of SARS-CoV-2: Transmission, Pathogenesis, Immunomodulation, Microflora Dysbiosis, and Clinical Implications. | Viruses | 2023 | 37376531 | PubTator, text mining | PubMed |
| Extraction, Purification, Structural Characteristics, Health Benefits, and Application of the Polysaccharides from Lonicera japonica Thunb.: A Review. | Molecules | 2023 | 37375383 | PubTator, text mining | PubMed |
| Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies. | Medicina (Kaunas) | 2023 | 37374319 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54567/papers?page=22